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Testing for improvement in prediction model
performance
Margaret Sullivan Pepea∗ , Kathleen F. Kerrb, Gary Longtona, Zheyu Wangb
New methodology has been proposed in recent years for evaluating the improvement in prediction performance
gained by adding a new predictor, Y , to a risk model containing a set of baseline predictors, X , for a binary
outcome D. We prove theoretically that null hypotheses concerning no improvement in performance are equivalent
to the simple null hypothesis that the coefficient for Y is zero in the risk model, P (D = 1|X, Y ). Therefore, testing
for improvement in prediction performance is redundant if Y has already been shown to be a risk factor. We
investigate properties of tests through simulation studies, focusing on the change in the area under the ROC
curve (AUC). An unexpected finding is that standard testing procedures that do not adjust for variability in
estimated regression coefficients are extremely conservative. This may explain why the AUC is widely considered
insensitive to improvements in prediction performance and suggests that the problem of insensitivity has to do with
use of invalid procedures for inference rather than with the measure itself. To avoid redundant testing and use
of potentially problematic methods for inference, we recommend that hypothesis testing for no improvement be
limited to evaluation of Y as a risk factor, for which methods are well developed and widely available. Analyses
of measures of prediction performance should focus on estimation rather than on testing. Copyright c 2011 John
Wiley & Sons, Ltd.
Keywords: Biomarker; Logistic regression; Receiver operating characteristic curve; Risk factors; Risk
reclassification

1. Introduction
Prediction modeling has long been a mainstay of statistical practice. The field has been re-energized recently due to the
promising identified through imaging and molecular biotechnologies. Accordingly, there has been renewed interest in
methods for evaluating the performance of prediction models. In particular, statisticians have been examining methods for
evaluating improvement in performance that is gained by adding a novel marker to a baseline set of predictors.
For example, novel markers for predicting risk of breast cancer beyond traditional factors in the Gail model [1, 2]
include breast density [3, 4] and genetic polymorphisms [5, 6, 7]. For cardiovascular outcomes, numerous studies have
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been performed in recent years to evaluate candidate markers for their capacities to improve upon factors in the standard
Framingham risk score [8]. Tzoulaki et al. [9] recently performed a meta-analysis of 79 such published studies.
A typical approach to analysis is to first determine the statistical significance of an observed association between
the novel marker, Y , and the outcome, D, controlling for the baseline predictors that we denote by X . The p-value is
usually derived from regression modeling techniques. If the contribution of Y to the risk model is found to be statistically
significant, the second step in the typical approach is to test a null hypothesis about improvement in prediction performance
for the model that includes Y in addition to X compared with the baseline model that includes only X . The most
popular statistic for testing improvement in prediction performance is the change in the area under the receiver operating
characteristic (ROC) curve [9]. Alternate measures are also used, including risk redistribution metrics [10, 11] and risk
reclassification metrics [12, 13, 14, 15, 16].
In this paper we question the strategy of testing the null hypothesis about no improvement in prediction performance
after testing the statistical significance of Y in the risk model. Our main theoretical result is that the null hypotheses are
equivalent. This implies that if Y is shown to be a risk factor, the prediction performance of the model that includes Y
cannot be the same as the performance of the baseline model, and there is no point to a second, redundant hypothesis test.
In Section 2 we prove our main result that the null hypothesis about Y as a risk factor can be expressed equivalently
as a variety of null hypotheses about the improvement in performance of the expanded model compared with the baseline
model. In Section 3 we discuss the choice of methodology for testing the common null hypothesis. We recommend use of
standard statistics derived from regression modeling of the risk as a function of X and Y . This recommendation is based
partly on the superior power achieved with likelihood based tests, but also on the new finding corroborated by other recent
reports in the literature [14, 17], that standard ROC methods for nested models appear to be excessively conservative. We
emphasize that estimation of the increment in prediction performance is more important than testing the null hypothesis
of no improvement. The results are discussed in Section 4 in the context of a real dataset concerning risk of renal artery
stenosis as a function of baseline predictors and a biomarker, serum creatinine.

2. Equivalent Null Hypotheses
Suppose that the outcome is binary, D = 1 for cases or D = 0 for controls, which could represent occurrence of an event
within a specified time period, say breast cancer within 5 years. Let risk(X) = P (D = 1|X) and risk(X, Y ) = P (D =
1|X, Y ) be the baseline and enhanced model risk functions respectively. To evaluate the incremental value of Y for
prediction over use of X alone, the first step is often to test the null hypothesis
H0 : risk(X, Y ) = risk(X).

(1)

We use subscripts (X, Y ) and X to indicate entities relating to use of risk(X, Y ) and risk(X), respectively. For example,
ROC(X,Y ) is the ROC curve for risk(X, Y ) while ROCX is the ROC curve for risk(X). The ROC curve for W is a plot of
P (W > w|D = 1) versus P (W > w|D = 0) and is a classic plot for displaying discrimination achieved with a variable
W [18] (Chapter 4). To test if discrimination provided by risk(X, Y ) is better than that provided by risk(X), one could
test
H0 : ROC(X,Y ) (·) = ROCX (·).

(2)

In ROC analysis the area under the ROC curve (AUC) is typically used as the basis of a test statistic. Then the null
hypothesis is more specifically stated as
H0 : AUC(X,Y ) = AUCX .

http://biostats.bepress.com/uwbiostat/paper379
(3)
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In the ROC framework another approach is to assess if, conditional on X , the ROC curve for Y is equal to the null
ROC curve [19]. This is particularly relevant when controls are matched by design to cases on X [20]. The corresponding
null hypothesis is
H0 : ROCY |X (f) = f, f ∈ (0, 1)

∀

X.

(4)

Several authors have proposed alternatives to ROC analysis for comparing nested prediction models. The predictiveness
curve displays the distribution of risk as the risk quantiles [10, 21, 22]. We write the cumulative distribution of risk as
F(X,Y ) (p) = P (risk(X, Y ) ≤ p) and FX (p) = P (risk(X) ≤ p). One can test if the risk distributions based on X or on
(X, Y ) are different by testing the null hypothesis
H0 : F(X,Y ) (·) = FX (·).

(5)

Another view is to consider the risk distributions in the case population (denoted with superscript D) and in the control
population (superscript D̄), separately. We could test
D
D
D̄
D̄
H0 : F(X,Y
) (·) = FX (·) and F(X,Y ) (·) = FX (·)

(6)

The integrated discrimination improvement statistic is a summary measure based on the difference in average risks
between cases and controls, M RD = E(risk(·)|D = 1) − E(risk(·)|D = 0). The MRD has many interpretations, for
example as the proportion of explained variation, as an R2 statistic, as Yates slope, and as an average Youden’s index
[15, 23, 24]. Pencina and others [12] define the integrated discrimination improvement (IDI) as IDI = MRD(X,Y ) −
M RDX and propose testing H0 : IDI = 0. That is, they propose testing
H0 : MRD(X,Y ) = MRDX .

(7)

Another interesting summary of the difference between the case and control risk distributions concerns proportions
with risk above the average population risk, ρ = P (D = 1). The above average risk difference is AARD = P (risk(·) >
ρ|D = 1) − P (risk(·) > ρ|D = 0). Like the MRD, the AARD has multiple interpretations and relates to existing measures
of prediction performance. The AARD is the continuous net reclassification index (NRI (>0), defined below) statistic [13]
for comparing a risk model with the null model that has no predictors in which all subjects are assigned risk P (D = 1) = ρ.
The AARD is also equal to the two-category NRI for comparing a model with the null model when the two risk categories
are defined as: low risk≡‘risk≤ ρ’ and high risk≡‘risk> ρ’. The AARD can also be considered as a measure relating
to the risk distribution in the population, F in equation (5). In particular Bura and Gastwirth [25] defined the total gain
statistic as the area between the predictiveness curve for risk(·) and the horizontal line at ρ, which is the predictiveness
curve for the null model. Gu and Pepe [24] showed that the standardized total gain, total gain/2ρ(1 − ρ), is ρAARD. One
can compare the performance of two risk models by evaluating the AARD values and testing the null hypothesis
H0 : AARD(X,Y ) = AARDX

(8)

The medical decision making framework has also been used to compare risk models. Vickers and Elkin [26] suggested
t
use of decision curves that plot the net benefit (NB(t)) ≡ ρP (risk(·) > t|D = 1) − (1 − ρ) 1−t
P (risk(·) > t|D = 0)
against t, the risk threshold. One could envision testing the equality of decision curves
H0 : NB(X,Y ) (·) = NBX (·)

(9)

to compare performance of a model that includes Y with one that does not. Baker [27, 28] suggests standardizing the net
benefit by the maximum possible benefit resulting in a relative utility measure. Testing equality of relative utility curves
Hosted by The Berkeley Electronic Press
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is the same as testing equality of decision curves in (9).
Risk reclassification methodology is yet another approach to comparing risk models. In this framework, for each
individual indexed by ı, risk(Xı , Yı ) is compared directly with risk(Xı ). The NRI statistic is a risk reclassification measure
that has gained tremendous popularity since its introduction by Pencina and colleagues in 2008 [12]. The continuous NRI
[13] is defined as
NRI(> 0) = 2{P [risk(X, Y ) > risk(X)|D = 1] − P [risk(X, Y ) > risk(X)|D = 0]}
The final null hypothesis that we consider testing is
H0 : NRI(> 0) = 0

(10)

Our key result is that all of the null hypotheses in equations (1) through (10) are equivalent.
Theorem 1
The following null hypotheses are equivalent

H01 : risk(X, Y ) = risk(X) with probability 1
⇔H02 : AUC(X,Y ) = AUCX
⇔H03 : ROC(X,Y ) (f) = ROCX (f)

∀

f ∈ (0, 1)

⇔H04

∀

f ∈ (0, 1)

∀

p ∈ (0, 1)

∀

p ∈ (0, 1)

∀

t ∈ (0, 1)

: ROCY |X (f) = f

⇔H05 : F(X,Y ) (p) = FX (p)
⇔H06

:

D
F(X,Y
) (p)

=

D
FX
(p)

and

⇔H07 : MRD(X,Y ) = MRDX
⇔H08

D̄
F(X,Y
) (p)

=

D̄
FX
(p)

i.e., IDI = 0 = 0

: AARD(X,Y ) = AARDX

⇔H09 : NB(X,Y ) (t) = NBX (t)
⇔H010

: NRI(> 0) = 0

Proof
That H01 implies each of H02 − H010 is obvious. Therefore we focus on showing that each of H02 − H010 imply H01 . We
start with H07 and work in reverse order through H06 , H05 , . . . , H02 . Then we show H08 , H09 , H010 ⇒ H01 .

(i) H07 implies H01
Pepe, Feng and Gu [23] write
MRD(X,Y ) − MRDX = {var(risk(X, Y )) − var(risk(X))}/P (D = 1)P (D = 0),
and because E(risk(X, Y )) = E(risk(X)) = Prob(D = 1) it follows that

var(risk(X, Y )) − var(risk(X)) = E(risk(X, Y ))2 − E(risk(X))2
= E(risk(X, Y ))2 − 2E(risk(X))2 +
E(risk(X))2 .
http://biostats.bepress.com/uwbiostat/paper379
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Since E{risk(X, Y )|X} = risk(X)
E(risk(X))2 . Therefore

we

have

E(risk(X)risk(X, Y )) = E(risk(X)E(risk(X, Y )|X)) =

var(risk(X, Y )) − var(risk(X)) = E(risk(X, Y ))2 − 2E(risk(X)risk(X, Y )) + E(risk(X))2
= E{risk(X, Y ) − risk(X)}2

Therefore if MRD(X,Y ) − MRDX = 0 it follows that E{risk(X, Y ) − risk(X)}2 = 0 and so risk(X, Y ) = risk(X)
with probability 1. That is, H01 follows.
(ii) H06 implies H01
Equality of the case specific distributions implies that the case specific means are equal: E(risk(X, Y )|D = 1) =
E(risk(X)|D = 1). Similarly E(risk(X, Y )|D = 0) = E(risk(X)|D = 0). Therefore, H06 implies H07 which we
have shown implies H01 .
(iii) H05 implies H01
The case specific distribution of risk can be derived from the population distribution of risk using Bayes’ theorem
[29].
P (risk(·) = r|D = 1) =

P (D = 1|risk(·) = r)P (risk(·) = r)
P (D = 1)

= rP (risk(·) = r)/P (D = 1)

A similar argument applies to the control specific distributions. Therefore equality of population risk distributions
in H05 implies equality of case and control specific risk distributions in H06 which in turn implies H01 .
(iv) H04 implies H01
H04 states that, conditional on X , the distributions of Y in the case and control populations are equal:
P (Y |D = 1, X) = P (Y |D = 0, X) = P (Y |X)

Using Bayes’ theorem it follows that
P (D = 1|Y, X)P (Y |X)
= P (Y |X)
P (D = 1|X)

and so P (D = 1|Y, X) = P (D = 1|X). That is H01 holds.
(v) H03 implies H01
Huang and Pepe [30] derived the one-one mathematical relationship between the ROC curve for risk(·) and the
predictiveness curve which characterizes the risk distribution. Therefore equality of ROC curves for risk(X, Y )
and risk(X) implies equality of the risk distributions, H05 , which in turn implies H01 .
(vi) H02 implies H01
We now show that equality of AUCs for risk(X, Y ) and risk(X) implies equality of the ROC curves, i.e.
H02 ⇒ H03 , from which H01 follows. A fundamental result from decision theory is that decision rules of the form
‘risk(X, Y ) > c’ have the best operating characteristics in the sense that when c is chosen to yield a false-positive
Hosted by The Berkeley Electronic Press
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rate f , f = P (r(X, Y ) > c(f)|D = 0), the corresponding true-positive rate t = P (r(X, Y ) > c(f)|D = 1) cannot
be exceeded by another decision rule based on (X, Y ). This result follows from Neyman-Pearson [31] and is
discussed in detail in McIntosh and Pepe [32].
It follows that the ROC curve for risk(X, Y ) is at least as high at all points than the ROC curve for any other
function of (X, Y ). In particular, the ROC curve for the function risk(X) cannot exceed ROC(X,Y ) (·) at any point.
Therefore, if the areas under ROC(X,Y ) (·) and ROCX (·) are equal, the functions must be equal at all points. That
is H03 must hold.
(vii) H08 implies H01
In the Appendix, Theorem A.1 considers the entity ROC(X,Y ) (tρ(X,Y ) ) − tρ(X,Y ) where tρ(X,Y ) ≡ P (risk(X, Y ) >
ρ|D = 0). But, by definition of tρ(X,Y ) and the ROC curve, we recognize ROC(X,Y ) (tρ(X,Y ) ) = P (risk(X, Y ) >
ρ|D = 1). Therefore Theorem A.1 states that if P (risk(X, Y ) > ρ|D = 1) − P (risk(X, Y ) > ρ|D = 0) =
P (risk(X) > ρ|D = 1) − P (risk(X) > ρ|D = 0) it follows that ROC(X,Y ) (t) = ROCX (t) ∀ t. That is, H08
implies H03 , which in turn implies H01 .
(viii) H09 implies H01
If NB(X,Y ) (t) = NBX (t)
NB(t) is defined as

∀

t, then in particular we have equality at t = ρ : NB(X,Y ) (ρ) = NBX (ρ). Recall that

NB(t) = ρP (risk > ρ|D = 1) − (1 − ρ)

t
P (risk > ρ|D = 0)
1−t

so at t = ρ we have
NB(ρ) = ρAARD.
Therefore H09 implies H08 , which in turn implies H01 .
(ix) H010 implies H01
We show below that P (risk(Y ) > ρ|D = 1) ≥ P (risk(Y ) > ρ|D = 0). The analogous statement when
conditioning on X is that
0 ≤ P (risk(X, Y ) > risk(X)|D = 1, X) − P (risk(X, Y ) > risk(X)|D = 0, X).

But
NRI(> 0) = 2{P (risk(X, Y ) > risk(X)|D = 1) − P (risk(X, Y ) > risk(X)|D = 0)}
= 2E{P (risk(X, Y ) > risk(X)|D = 1, X) − P (risk(X, Y ) > risk(X)|D = 0, X)}

So if NRI(> 0) = 0 it follows that for all X with probability 1 we have
P (risk(X, Y ) > risk(X)|D = 1, X) − P (risk(X, Y ) > risk(X)|D = 0, X) = 0

The corollary to Theorem A.1 in the Appendix then implies that the ROC curve for Y conditional on X is the null
ROC curve. That is, for all X with probability 1, ROCY |X (f) = f ∀ f .
In other words H04 holds, which in turn implies H01 .

http://biostats.bepress.com/uwbiostat/paper379
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To complete the proof we need to prove our assertion that P (risk(Y ) > ρ|D = 1) ≥ P (risk(Y ) > ρ|D = 0). Using
Bayes’ theorem this can be restated as
P (D = 1|risk(Y ) > ρ)
P (D = 0|risk(Y ) > ρ)
≥
P (D = 1)
P (D = 0)
a
1−a
≥
b
1−b

But this holds because we have a ≥ b, implying that 1 − a ≤ 1 − b, from which it follows that a/b ≥ 1 ≥
(1 − a)/(1 − b).


Theorem 1 is a mathematical result involving the functions risk(X, Y ) and risk(X) and performance measures that are
functionals of them. No modeling of the risk functions is assumed. In the next section we consider practical implications
of Theorem 1 for data analysis in which models for risk(X, Y ) and risk(X) may be fit to data.

3. Recommendations for Hypothesis Testing
The equivalence of the various null hypotheses in Theorem 1 should not be confused with the equivalence of different
hypothesis tests. Two tests can have the same null hypothesis but still be different tests and give different results on a
dataset because they are based on different test statistics with different statistical properties. However, it does not make
sense to test the same null hypothesis twice — a single test should be chosen. How does one choose the statistical test for
the null hypothesis of no incremental value?
There are many possible choices, but we focus here on the choice between a test for the coefficient for Y in a regression
model of the risk function risk(X, Y ) and the change in the AUC for the ROC curves associated with estimated risk
functions, risk(X) and risk(X, Y ). To make the discussion concrete we consider the Wald test based on βbY where βY is
[ = AUC
[ (X,Y ) − AUC
[ X where
the coefficient for Y in a model for risk(X, Y ) and a test based on the difference ∆AUC
[ is calculated with the empirical distributions of the fitted values for the risk function in subjects with D = 1 and
AUC
D = 0.
3.1. Testing the regression coefficient has highest power
When the data are independent identically distributed observations, the Wald test is asymptotically the most powerful test
for testing H01 − H010 , and so, at least in this classic setting, the test based on βbY is to be preferred. We see the power
[ is
advantage demonstrated in the second row of the simulation results in Table 1 where the procedure based on ∆AUC
fixed to have size equal to the nominal level of 0.05. It is also instructive to consider the special case where there are no
[ is equivalent to the nonparametric two-sample Wilcoxon statistic while βbY from
baseline covariates. In that setting ∆AUC
a linear logistic risk model is asymptotically equivalent to the difference in means and so is equivalent to a two-sample
Z-statistic. The Z-statistic is well known to have superior performance compared with the Wilcoxon statistic for normal
[ for normally distributed data and no
data. That is, testing using βbY is well known to be superior to testing using ∆AUC
baseline covariates.
3.2. Standard tests of performance measures may not be valid
[ test.
From a practical point of view, there are additional issues that make the Wald test more desirable than the ∆AUC
In particular, procedures for fitting risk regression models and for testing coefficients in regression models are highly
Hosted by The Berkeley
Electronic Press
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[ uses the fitted values for risk(X, Y ) and risk(X) as data inputs to a
models. The typical approach to testing with ∆AUC
test of equal AUCs for two diagnostic tests such as the DeLong test [33] or the resampling based test [34]. The fact that
the coefficients in the fitted values are estimated from the data is ignored in these testing procedures.
We used simulation studies to investigate the properties of these tests in a simple scenario. We generated data for X
and Y as independent and normally distributed with standard deviation 1 in cases (D = 1) and controls (D = 0). The
mean of X was 0.74 in cases and 0 in controls yielding an AUC of 0.7 for the baseline risk model. The mean of Y was 0
in cases and in controls under scenarios simulating the null setting for evaluating size, while the means were 0.37 or 0.74
in cases and 0 in controls under scenarios simulating the alternative setting for evaluating power. We see from the third
and fourth rows in Table 1 that standard tests ignoring sampling variability in the estimated risk regression coefficients
are extremely conservative. Both the DeLong test [33] that uses the normal approximation and a standard error formula
and the test using percentiles of the bootstrap distribution [34] have size less than .005 with sample sizes as large as 100
cases and 900 controls. The conservatism is due to estimating the coefficients in the nested models since the same tests
comparing X alone to another independent marker with equal performance were not conservative with comparable sample
sizes (data not shown).
[ test in the hope that acknowledging sampling variability in the
We implemented an alternative version of the ∆AUC
estimated regression coefficients would lead to a test with correct size. This approach used the bootstrap. We resampled
[ for each resampled dataset. Tests using
observations from the original dataset, fit the risk models, and calculated ∆AUC
[
percentiles of the bootstrap distribution (results shown in line 5 of Table 1 as ∆AUC-adjusted)
or the standard deviation of
the bootstrap distribution (results not shown) remained conservative, though they were less conservative than procedures
not adjusting for variability in regression coefficients. We conclude that all currently available procedures for testing
[ are unacceptably conservative in the classic scenarios we studied. From Table 1 we
incremental value based on ∆AUC
observe that as a consequence they have extremely low power compared with the Wald test for βY .

3.3. What if models are not well calibrated?
The results of Theorem 1 have implications for the analysis of data when the functional form of risk(X, Y ) is
approximately correct. That is, for testing the null hypothesis of no improvement in prediction performance the theorem
implies that we can test if regression coefficients for Y are zero, but this requires that the regression model for risk(X, Y )
is correctly specified at least under the null. If the form of the regression model for risk(X, Y ) under the null is in doubt,
i.e., if risk(X) is misspecified, tests based on the regression model may not be valid.
With misspecified model forms one might still use the risk modeling exercise to generate combination scores,
∗
∗
d
d (X). Under these circumstances we believe that a case can be made for considering tests of increment
risk (X, Y ) and risk
in performance using statistics based on performance measures such as ∆AUC instead of tests based on the regression
coefficient for Y . Note that with this approach one should derive the combination scores in a training set and test for
equality of performance in an independent test dataset since our simulation results (Table 1) and others [14, 17] show that
current testing procedures are not valid if both steps are undertaken in the same dataset.
It is our opinion however that poorly calibrated models are not acceptable in the context of risk prediction research. It is
unethical to apply a model known to be poorly calibrated when calculating a person’s risk. The assessment of calibration
must be a priority and should precede assessment of prediction performance. A minimum requirement is weak calibration
defined by :
Pb(D = 1|risk(·) = r) ≈ r

so that of persons whose risks are calculated as r, approximately a proportion r are cases. If a model is poorly calibrated
in the weak sense, it is simply not valid for the population and its performance characteristics are of less interest. One
can and should at least recalibrate the models to the study population. The performance characteristics of the recalibrated
http://biostats.bepress.com/uwbiostat/paper379
models in the study population will then be of interest and can be assessed.
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3.4. Recommendation

Our recommendation is to ensure the use of well calibrated risk models and to base hypothesis testing on βbY rather than
[ Procedures based on ∆AUC
[ do not have correct size. Kerr et al [35] found similar problems for the IDI statistic
on ∆AUC.
[ could be developed to properly account for
under the null. It is possible that new approaches to testing based on ∆AUC
sampling variability in the fitted risk values and thereby yield appropriately sized tests. However, even if such procedures
were developed, we have argued and observed in Table 1 (line 2) that tests based on βbY are still likely to be more powerful,
at least when likelihood based procedures are used to estimate parameters in the risk models. Therefore testing based on
βbY would still be the better choice.
More important than testing if there is any increment in prediction performance is estimating the size of the gain in
performance. The sizes of the regression coefficients for Y and X in risk(X, Y ) are not sufficient because prediction
performance depends on the population distribution of the predictors (X, Y ) in addition to the conditional probability
function P (D = 1|X, Y ) = risk(X, Y ). A variety of measures to quantify the prediction performance of a risk model
were described in Section 2 and a comparison of the measures calculated with risk(X ) and risk(X, Y ) constitutes the
corresponding increment in performance due to Y . The field of risk prediction has not yet settled debates about which
are the best measures for quantifying performance increment and we do not debate this question further here. Our
recommendation is to focus on estimating a compelling measure of increment in prediction performance. Any testing
should be limited to testing whether Y is a risk factor when controlling for X in a regression model.

4. Application to a Renal Artery Stenosis Dataset
Diagnosis of stenosis in the renal artery involves a risky surgical procedure and is only undertaken for patients deemed
likely to have a positive finding. The risk of having renal artery stenosis is estimated from clinical data in order to
guide decisions about undergoing invasive surgery for definitive diagnostic procedures. Data for 426 patients who were
surgically assessed for renal stenosis were reported by Janssens and others [36]. We consider the improvement in prediction
performance that is gained by adding serum creatinine to the baseline predictors.
We randomly chose one third of the observations (n = 142) to generate a baseline risk predictor X that is a combination
of the candidate clinical variables. Using linear logistic regression we found that age, body mass index (BMI) and
abdominal bruit (bruit) were highly significantly associated with renal stenosis but that gender, hypertension and vascular
stenosis were not. We refit the model including only age (in years), BMI (kg/m2 ) and bruit (yes=1, no=0) to derive the
linear combination
X = 0.93 × age − 0.24 BMI + 1.58 × bruit.
We then evaluated the performances of risk models based on X and on the combination of X and Y = log (serum
creatinine) using the remaining two thirds of the data (n = 284).
Linear logistic models were fit:

Baseline: logitP (D = 1|X) = α0 + α1 X
Enhanced: logitP (D = 1|X, Y ) = β0 + β1 X + β2 Y.
Figure 1 shows that these models are well calibrated to the study cohort since observed event rates in each decile of
modeled risk (shown as open circles) are approximately equal to the modeled risks (shown as the points on the risk
quantile curves). Hosmer-Lemeshow goodness of fit statistics [10, 38] do not provide any evidence against the null of
Hosted
The
Electronic Press
good calibration (p-values of 0.39 for the baseline model, risk(X), and 0.98 for the enhanced model,
riskby
(X,
Y Berkeley
)).
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The Wald test for H0 : β2 = 0 is highly significant with p < 0.001 (Table 2). According to Theorem 1 we can conclude
that prediction model performance is improved by addition of Y to the model. Nevertheless we implemented tests based
on ∆AUC as well to compare inference. The test for equality of AUCs is also significant but with much weaker p-value,
p = 0.014, using the DeLong variance formula and p = 0.012 using percentiles of the bootstrap distribution. Recall that
these tests do not acknowledge variability in the estimated regression coefficients (βb1 , βb2 ) and are extremely conservative.
Bootstrapping that incorporated refitting the risk model in each resampled dataset yielded a stronger p-value (p <0.001).
However, in accordance with our recommendation in Section 3, the test based on βb2 yielded the strongest evidence that
prediction performance is improved by including serum creatinine as a predictor.
We repeated the analysis using a weaker marker, Y ∗ , for illustration. Here Y ∗ = Y + ε where ε is a standard normal
random variable, adding noise to Y . In this analysis the coefficient for Y ∗ is highly statistically significant (p = 0.009,
Table 2) while the standard tests based on ∆AUC are not (p = 0.12 using the DeLong variance formula and p = 0.13
using percentiles of the bootstrap distribution). The bootstrapped adjusted ∆AUC test that refits the models is significant,
p = 0.02, but not as convincing as the test for Y ∗ in the risk model (p = 0.009). Again, this is consistent with our simulation
results and theoretical expectations and supports our recommendation for testing the null hypothesis of no performance
improvement on the basis of the regression coefficient for Y in the enhanced risk model, risk(X, Y ).
Estimates of prediction performance are shown in Table 3 for the baseline and enhanced risk models. Confidence
intervals were calculated using 2.5th and 97.5th percentiles of bootstrap distributions with models refit in each
bootstrapped dataset. We estimated that the area under the ROC curve increased from 0.78 to 0.82 with addition of
serum creatinine. We also considered a point on the ROC curve. In particular, setting the risk threshold so that 80% of the
cases are sent for the invasive diagnostic renal arteriography, we find that the proportion of controls who unnecessarily
undergo the procedure, denoted by ROC−1 (0.8) in Table 3, decreases from 0.44 to 0.31. Note that Pfeiffer and Gail
[37] recommend calculating the percent needed to follow (PNF) that is a simple function of ROC−1 (f) : PNF(f) =
ρf + (1 − ρ)ROC−1 (f). Therefore the PNF decreased from 0.55 to 0.45. The IDI statistic is the change in the MRD
statistic and is calculated as 0.06 while the conceptually similar change in the AARD is 0.03. The continuous-NRI statistic
is NRI(> 0) = 0.54. Note that the NRI is measured on a scale from 0 to 2, unlike most other measures that are restricted to
(0,1). We calculated the net benefit using a risk threshold of 0.25. This threshold implicitly assumes that the net benefit of
diagnosis for a subject with renal artery stenosis is 3 times the net cost of the diagnostic procedures for a subject without
stenosis since the cost-benefit ratio = risk threshold/(1-risk threshold) [26]. The maximum possible benefit of a risk model
in this population would be that associated with diagnosing all 67 (24%) subjects who have renal stenosis and not sending
any controls for the diagnostic procedure. We calculate that the net benefit is 27.1% of maximum with use of the baseline
model and 36.4% of maximum with use of the model that includes serum creatinine. We see that 95% confidence intervals
for some but not all measures of improvement in performance exclude the null value of 0. However the single test of
H0 : β2 = 0 is sufficient to conclude that performance is improved.

5. Discussion
The main result of this paper is that the common practice of performing separate hypothesis tests, for the coefficient of Y
in the risk prediction model and for the change in performance of the model, is literally testing the same null hypothesis
twice. Vickers et al. [17] make a heuristic argument for this point. We have proven the result with formal mathematical
theory. Testing the same null hypothesis in multiple ways is poor statistical practice and should be replaced with a more
thoughtful strategy for analysis that employs a single test of the null. Arguments in favor of basing the single test on
the regression coefficient for Y in a risk model include: (i) that such tests are most powerful asymptotically; and (ii)
that techniques are well developed and widely available for performing such tests. This strategy relies on employing risk
models that have approximately correct forms. We have argued that good calibration is http://biostats.bepress.com/uwbiostat/paper379
a crucial aspect of risk model
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assessment. If necessary models should be recalibrated to the population of interest prior to assessing model performance.
After recalibrating the models, testing based on regression coefficients is the most powerful and reliable approach to
detecting if there is any improvement in predictor performance by adding a predictor to a baseline model.
After testing if there is any improvement in prediction performance, the next task is to estimate the extent of
improvement achieved. How to quantify the improvement in performance is a topic of much debate in the literature.
A multitude of metrics exist, including ∆AUC, ∆MRD, ∆AARD, approaches based on risk reclassification tables
[13, 15, 16], approaches based on the Lorenz curve [37] and approaches based on medical decision making [7, 26, 28, 39].
This paper does not seek to provide guidance on the choice of measure, but we do emphasize that estimation of the
improvement gained is crucial. Moreover, if hypothesis testing based on performance measures is employed, it should be
with regard to a null hypothesis concerning minimal improvement, H0 : performance improvement ≤ minimal rather than
any improvement, H0 : performance improvement = 0. The exercise of setting standards for minimal improvement may
have the added benefit of helping us to choose a clinically relevant measure of performance improvement.
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Table 1. Performance of two-sided nominal 0.05 level tests. Tests are based on βbY , the estimated regression coefficient for Y in the risk model logit risk(X, Y ) =
[ = AUC
[ (X,Y ) − AUC
[ X . Tests based on ∆AUC
[ were: ‘adjusted’ if regression coefficients were estimated from each bootstrap
β0 + βX X + βY Y and on ∆AUC
d
d
resampled dataset; and ‘standard’ if bootstrap resampling (bootstrap) or DeLong standard error (se) calculation used risk(X,
Y ) and risk(X)
derived from the
original dataset. Data were simulated with (X, Y ) ∼ N (0, 1) in controls, X ∼ N (0.74, 1) in cases, Y ∼ N (0, 1) in cases under the null and Y ∼ N (0.37, 1) in cases
under the alternative. 1000 simulations for each scenario and 1000 bootstrap samples per analysis.

Size(βY = 0)

Test Statistic
bY
β
[
∆AUC-size
fixed†
[
∆AUC-se-standard
[
∆AUC-bootstrap-standard
[
∆AUC-bootstrap-adjusted

n0 = nD̄ = 50

0.048
0.050
0.000
0.000
0.012

nD = 100,nD̄ = 900

0.051
0.050
0.002
0.002
0.014

nD = nD̄ = 50

0.388
0.256
0.039
0.047
0.183

Power (βY = 0.37)
nD = 100,nD̄ = 900
0.908
0.799
0.280
0.291
0.666

Power (βY = 0.74)
nD = 100,nD̄ = 900
0.928
1.000
0.775
1.000
0.356
0.988
0.365
0.988
0.692
0.999

nD = nD̄ = 50

†
The rejection thresholds for this test were chosen using the null distribution calculated from 50,000 simulated datasets. In practice the null
distribution is unknown so this test cannot be applied.
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Table 2. Logistic regression models for risk of renal artery stenosis fit to data for 284 patients. The addition of Y =
log(serum creatinine) to a model including the baseline covariate X = 0.93 age − 0.24 BMI + 1.58 bruit is assessed.
Also shown are results for a model including Y ∗ = Y + ε where ε ∼ N (0, 1) random variable. Log odds ratios are
displayed along with standard errors and p-values.

Intercept
Baseline Model (X)
coefficient
se
p-value
Enhanced Model (X, Y )
coefficient
se
p-value
Enhanced Model (X, Y ∗ )
coefficient
se
p-value

X

Y or Y ∗

0.03
0.22
0.88

0.74
0.11
<0.001

—
—
—

−0.20
0.24
0.39

0.66
0.12
<0.001

0.70
0.19
<0.001

−0.05
0.23
0.81

0.71
0.12
<0.001

0.34
0.13
0.009
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Table 3. Performance of baseline and enhanced models for prediction of renal artery stenosis and performance
improvement with 95% confidence interval calculated with 1000 bootstrap samples.
Baseline Model Enhanced Model
Performance Improvement†
Performance Measure
X
(X, Y )
ROC Area
AUC
0.78
0.82
0.04 (0.01,0.08)
FPR at TPR=0.8
ROC−1 (0.8)
0.44
0.31
−0.12 (−0.22,0.06)
Mean Risk Difference
MRD
0.20
0.26
0.06∗ (0.015,0.13)
Above Average Risk Difference AARD
0.43
0.46
0.03∗∗ (−0.05,0.13)
Continuous NRI
NRI (> 0)
—
—
0.54 (0.23,0.84)
Net Benefit at 0.25
NB (0.25)
6.4%
8.6%
2.2% (−0.6%,5.1%)
† Performance improvement is defined as the difference between the measure for the enhanced model and that for the baseline model
for all measures except for the NRI.
∗ Also known as the IDI statistic.
∗∗ Also known as the Total Gain statistic.
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Figure 1. Predictiveness curves to assess calibration of baseline and enhanced risk models for renal artery stenosis. Shown are the modeled risk quantiles (as curves) and the
observed event rates within each decile of modeled risk (as open circles). Hosmer-Lemeshow statistics corresponding to the plots have p-values equal to 0.39 (baseline model) and
0.98 (enhanced model).
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Appendix
We use the following notation
D̄
tρX ≡ 1 − FX
(ρ) = P (risk(X) > ρ|D = 0)
D̄
tρ(X,Y ) ≡ 1 − F(X,Y
) (ρ) = P (risk(X, Y ) > ρ|D = 0)

We also assume that the distributions of risk(X, Y ) and risk(X) are absolutely continuous. This implies that their ROC
curves have second derivatives.

Theorem A.1

ROC(X,Y ) (tρ(X,Y ) ) − tρ(X,Y ) = ROCX (tρX ) − tρX
⇔

ROC(X,Y ) (t) = ROCX (t)

∀

(A.1)

t

Proof
For W = risk(X) or W = risk(X, Y ) it is well known that ROCW (t) − t is a concave function (Pepe 2003, page
71 [18]). Therefore ROC(X,Y ) (t) − t has a unique maximizer. Moreover, the maximizer occurs when ROC0(X,Y ) (t) = 1.
Arguments below in the proof of Corollary A.1 show that this implies ROC(X,Y ) (t) − t is maximized at tρ(X,Y ) .
Since ROC(X,Y ) (t) ≥ ROCX (t) ∀ t, we have
ROC(X,Y ) (tρX ) − tρX ≥ ROCX (tρX ) − tρX
and equation (A.1) implies therefore that
ROC(X,Y ) (tρX ) − tρX ≥ ROC(X,Y ) (tρ(X,Y ) ) − tρ(X,Y ) .
It follows that tρX = tρ(X,Y ) because, as noted above, ROC(X,Y ) (t) − t has a unique maximizer at tρ(X,Y ) . This also implies
by equation (A.1) that ROC(X,Y ) (tρ ) = ROCX (tρ ) where we now use the notation tρ for the common value of tρ(X,Y ) and
tρX .
Next we show that ROC0X (t) ≤ ROC0(X,Y ) (t) when t < tρ . To show this we suppose that ROC0X (t) > ROC0(X,Y ) (t)
for some t < tρ and construct decision rules based on (X, Y ) with an ROC curve exceeding ROC(X,Y ) on a subinterval
of (0, tρ). If ROC0X (t) > ROC0(X,Y ) (t) at some point t, by continuity of ROC0X and ROC0(X,Y ) we have ROC0X (t) >
ROC0(X,Y ) (t) on an interval (a, b) ⊂ (0, tρ ). Let ra denote the risk threshold corresponding to the false positive rate
a
a
and consider the family of decision rules that classify positive if {‘risk(X, Y ) > r(X,Y
) ’ or [‘risk(X, Y ) < r(X,Y ) and
(t)

a
b
risk(X) < rX
and risk(X) > k ’ for k > rX
]}. These decision rules have an ROC curve equal to ROC(X,Y ) at t = a
0
and with derivative higher than ROC(X,Y ) over (a, b). Therefore this ROC curve exceeds ROC(X,Y ) over (a, b). But
this is impossible because the Neyman-Pearson lemma implies that ROC(X,Y ) (t) is optimal at all t. In particular
ROC(X,Y ) (t) ≥ ROCX (t) at all t.
Recall from above that

0 = ROC(X,Y ) (tρ ) − ROCX (tρ ) =

Z

0

tρ

(ROC0(X,Y ) (t) − ROC0X (t))dt.
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But having shown that the integrand is ≥ 0, we must conclude that the integrated is 0,
ROC0(X,Y ) (t) = ROC0X (t)

∀

t < tρ .

Moreover equality of ROC(X,Y ) (t) and ROCX (t) at t = 0 and at t = tρ implies
ROC(X,Y ) (t) = ROCX (t)
Similar arguments show that ROC(X,Y ) (t) = ROCX (t)

∀

∀

t < tρ .

t > tρ .


Corollary A.1
Let ROCω (·) be the ROC curve for the risk function risk(ω) = P (D = 1|ω). We show that

ROCω (tρω ) = tρω
⇔

ROCω (t) = t

∀

(A.2)
t ∈ (0, 1)

Proof
ROCω (t) − t is maximized at the point where ROC0ω (t) = 1. Bayes’ theorem implies that
logitP (D = 1|risk(ω) = r) = logitρ + log ROC0 (trω )
where trω = P (risk(ω) > r|D = 0). When ROC0 (tω (r)) = 1 therefore, P (D = 1|risk(ω) = r) = ρ. That is, the point that
maximizes ROCω (t) − t is tρω . We write
sup|ROCω (t) − t| = ROCω (tρω ) − tρω

(A.3)

but (A.2) then implies that sup|ROCω (t) − t| = 0. In other words ROCω (t) = t ∀ t ∈ (0, 1). Note that equation (A.3)
also follows from the fact that both sides of (A.3) were show to equal the standardized total gain statistic (see equations
(6) and (7) of Gu and Pepe [24]).
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